<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184741</url>
  </required_header>
  <id_info>
    <org_study_id>B211-11</org_study_id>
    <nct_id>NCT02184741</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of GB-0998 in Unexplained Primary Recurrent Miscarriage</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blinded Study With GB-0998 for Unexplained Primary Recurrent Miscarriage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Blood Products Organization</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Japan Blood Products Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the safety and efficacy of intravenous immunoglobulin therapy using GB-0998 in
      women with four or more miscarriages by carrying out randomized, placebo-controlled,
      double-blinded study．
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of continued pregnancy</measure>
    <time_frame>at the beginning of 22th gestational week</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Recurrent Miscarriage</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB-0998</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of GB-0998 (Immunoglobulin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB-0998</intervention_name>
    <description>Subjects recieved GB-0998 at a dose of 400mg/kg/day for five days until the 6th gestational week.</description>
    <arm_group_label>GB-0998</arm_group_label>
    <other_name>Intravenous Immunoglobulin （Venoglobulin®IH，2.5g/50ml）</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects recieved saline of the same volume as GB-0998 for five days until the 6th gestational week.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who have no experience of a live birth.

          2. Patients with four or more miscarriages.

          3. Patients who have not any obvious cause of recurrent miscarriage, or who have a
             miscarriage even after appropriate treatments.

        Exclusion Criteria:

          1. Patients who have abnormality with karyotype analysis in either the patients or their
             partners.

          2. Patients who were diagnosed antiphospholipid antibody syndrome according international
             criteria.

          3. Patients with no receiving of appropriate treatment in spite of diagnosis of diabetes
             or impaired glucose tolerance.

          4. Patients who have experience of receiving IVIg as the treatment of recurrent
             miscarriages.

          5. Patients with receiving treatment of malignancy.

          6. Patients with history of thromboembolism.

          7. Patients with history of shock or hypersensitivity to GB-0998.

          8. Patients with hereditary fructose intolerance or IgA deficiency.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hideto Yamada, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology,Kobe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigeru Saito, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology,University of Toyama</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japan Blood Products Organization</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyuki Ishikawa</last_name>
      <email>c-development@jbpo.or.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVIG</keyword>
  <keyword>Unexplained Recurrent miscarriage</keyword>
  <keyword>Recurrent abortion</keyword>
  <keyword>Intravenous immunoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

